Global Generic Injectables Market to Reach USD 99.2 Billion by 2033, Propelled by Favorable Government Initiatives

November 07, 2024 | Healthcare

The latest report by IMARC Group, titled “Generic Injectables Market Report by Therapeutic Area (Oncology, Anaesthesia, Anti-infectives, Parenteral Nutrition, Cardiovascular), Container (Vials, Ampoules, Premix, Prefilled Syringes), Distribution Channel (Hospitals, Retail Pharmacy), and Region 2025-2033,” finds that the global generic injectables market size reached USD 51.0 Billion in 2024. Generic injectables are alternative drugs that are bio-equivalent to their branded counterparts. They contain similar active ingredients, strength, quality, effectiveness, intended use, and dosage. These injectables help in the easy absorption of drugs into the body in liquid form, which reduces the frequency of dosage administration without affecting the effectiveness of the treatment. They are also cost-effective as they do not require investments in research and development (R&D) and promotional activities.

Global Generic Injectables Market Trends:

Nowadays, the governing authorities of numerous countries are undertaking favorable initiatives to support the manufacturing of generic injectables. This can be accredited to the rising drug shortage and upcoming patent expiry of several branded drugs. Besides this, the increasing prevalence of chronic diseases like diabetes, cardiovascular disorders, and Alzheimer’s and the rising geriatric population that is more susceptible to such ailments are positively influencing the market growth. Moreover, generic injectables are widely adopted by patients who are unable to take medicines by mouth and have poor intestinal absorption. In addition, various key players are engaging in mergers and acquisitions (M&As) and partnerships to develop complex and differentiated products, which is creating a favorable market outlook across the globe. Furthermore, the emergence of self-injection devices, the improving healthcare infrastructures in developed and developing economies, and rapid technological advancements in drug delivery systems are some of the other factors augmenting the market growth. Looking forward, IMARC Group expects the market value to reach USD 99.2 Billion by 2033, exhibiting a CAGR of 6.88% during the forecast period (2025-2033). 

Market Summary:

  • On the basis of the therapeutic area, the market has been classified into oncology, anaesthesia, anti-infectives, parental nutrition and cardiovascular. Amongst these, the oncology segment holds the largest market share. 
  • Based on the container, the market has been categorized into vials, ampoules, premix, and prefilled syringes. 
  • On the basis of the distribution channel, the market has been bifurcated into hospitals and retail pharmacies. At present, hospitals exhibit a clear dominance in the market. 
  • Region-wise, North America holds the leading position in the market. Other major regions include Europe, Asia, Middle East and Africa, and Latin America.
  • The competitive landscape of the market has been studied in the report, with some of the key players being Baxter International Inc., Fresenius Kabi AG, Hikma Pharmaceuticals plc, Pfizer Inc., Sagent Pharmaceuticals Inc. (Nichi-Iko Pharmaceutical Co. Ltd.), Sandoz International GmbH (Novartis International AG) and Sanofi S.A.


Report Coverage:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Segment Coverage Therapeutic Area, Container, Distribution Channel, Region
Region Covered  Asia, Europe, North America, Latin America, Middle East and Africa
Companies Covered Baxter International Inc., Fresenius Kabi AG, Hikma Pharmaceuticals plc, Pfizer Inc., Sagent Pharmaceuticals Inc. (Nichi-Iko Pharmaceutical Co. Ltd.), Sandoz International GmbH (Novartis International AG) and Sanofi S.A.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group

USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter : @imarcglobal

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Generic Injectables Market to Reach USD 99.2 Billion by 2033, Propelled by Favorable Government Initiatives
Purchase Options
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials